Abbott launches digital health app for neurostimulation in Canada

Abbott (NYSE:ABT) announced today that it received Health Canada licensing for and launched its NeuroSphere Virtual Clinic.

The Abbott Park, Illinois-based company designed the remote programming technology — the first of its kind in Canada — with compatibility with Abbott’s suite of neuromodulation technologies, offering the potential to increase access to optimal treatment for patients living with chronic pain, Parkinson’s disease, or essential tremors who might otherwise have difficulty receiving care from their healthcare provider due to location or being unable to travel to seek care.

Users can receive care anywhere by connecting with their doctor through a secure in-app video chat and an integrated remote programming feature. Clinicians can prescribe new treatment settings remotely to the patient’s neurostimulation device using the clinician programmer app and a new, simple, and secure remote care connection.

In April, the company…

Read more
  • 0

Health Canada licenses Medtronic’s GI Genius endoscopy module for colonoscopy

[Image from Medtronic]Medtronic (NYSE:MDT) announced today that it received Health Canada license for its GI Genius intelligent endoscopy module.

The company’s Brampton, Ontario-based Medtronic Canada subsidiary received the license for the computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

According to a news release, the GI Genius intelligent endoscopy module — which Medtronic touts as compatible with any colonoscope video — provides physicians with a tool to fight against colorectal cancer.

GI Genius uses advanced AI to highlight the presence of possible precancerous lesions with a visual marker in real-time. Advanced algorithms process the colonoscopy images to identify and mark polyp abnormalities, including ones that could otherwise go detected under the observation of the human eye.

Read more
  • 0

Abbott wins CE mark for Amplatzer steerable delivery sheath

Abbott (NYSE:ABT) announced today that it received CE mark and Health Canada approval for its Amplatzer steerable delivery sheath.

The company touts the Amplatzer sheath as the first steerable delivery sheath to be developed specifically for minimally invasive left atrial appendage (LAA) occlusion (or closure) procedures for patients diagnosed with atrial fibrillation who are at risk of ischemic stroke, according to a news release.

Abbott Park, Ill.-based Abbott designed the sheath for use with its Amplatzer Amulet LAA occluder. The company said the sheath also features bi-directional steering and an auto-lock setting for more accurate alignment with the LAA.

Additionally, the sheath includes a hemostasis valve designed to stabilize blood flow and minimize blood loss during the procedure. Abbott said the new design reduces the need for catheter manipulation or exchanges, thus reducing issues that slow down procedures or cause further blood loss.


Read more
  • 0

Canada approves J&J Vision’s drug-eluting contact lens

Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens.

Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

CAE receives Health Canada nod for CAE Air1 ventilator

The CAE Air1 ventilator (CNW Group/CAE INC.)

CAE (NYSE:CAE) announced today that its CAE Air1 ventilator received certification from Health Canada and is set to treat people with COVID-19.

Two months ago, the Canadian government issued a contract to CAE to manufacture and supply 10,000 ventilators amid the COVID-19 pandemic. The devices deliver pressure control, volume control and pressure support ventilation using room air or pressured oxygen.

The CAE Air1 ventilator includes an intuitive touchscreen interface and is bundled with on-demand ventilator training, adaptive e-learning modules related to COVID-19 patient management and 24/7 customer support.

Montreal-based CAE said in a news release that it will begin shipping hundreds of CAE Air1 machines to the Canadian government every week.

“Since the beginning of the pandemic, CAE was the first to receive certification from Heal…

Read more
  • 0

Canada orders 37 million syringes from BD in anticipation of COVID-19 vaccine

Canada reportedly signed a contract to purchase 37 million syringes from Becton Dickinson (NYSE:BDX) in preparation for a potential COVID-19 vaccine.

A report in The Record revealed that Public Services & Procurement Minister Anita Anand said the country made a purchase order from the Canadian branch of BD in an effort to make sure Canada is ready for mass vaccinations if the cure for COVID-19 is discovered. There is no definitive timeline for the delivery of the syringes as of now.

The Record cited Statistics Canada as reporting that more than 38 million people comprise the country’s population, one million more than the total number of syringes agreed upon in the contract. Canada Chief Public Health Officer Theresa Tam said the order represents the “maximum number of Canadians who may wish to be vaccinated,” according to the report.

Currently, Chinese pharmaceutical company CanSino Biologics is collabo…

Read more
  • 0

Health Canada authorizes Abbott COVID-19 antibody test

Abbott (NYSE:ABT) announced today that Health Canada has granted interim authorization for its Architect SARS-CoV-2 IgG serology test for COVID-19.

The Abbott Park, Ill.-based company won an FDA emergency use authorization and the CE Mark for the same antibody test for use on its Architect system in April. The test is designed to detect the IgG antibody, a protein that the body produces in the late stages of infection and may remain up to months after a person has recovered from the novel coronavirus.

A recent study published in the Journal of Clinical Microbiology found that Abbott’s SARS-CoV-2 IgG antibody test had 99.9% specificity and 100% sensitivity for detecting the IgG antibody in patients 17 days or more after symptoms began. Abbott has come under scrutiny for the accuracy of one of its COVID-19 molecular diagnostic tests.

The company said it expects to begin shipping antibody tests to Canada this week and intends to distribute 30 million …

Read more
  • 0